Loading financial data...

REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) Financial Statements | Global Financial Data

REVIVA PHARMACEUTICALS HOLDINGS, INC.

RVPHSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1742927

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Research and Development Expense	$31.4M	$15.5M	$4.9M	$295.1K	$195.7K
Operating Expenses	$39.5M	$19.3M	$10.1M	$2.4M	$376.9K
Operating Income (Loss)	-$39.5M	-$19.3M	-$10.1M	-$2.4M	-$376.9K
Interest Expense	—	—	—	$1.5M	$469.4K
Nonoperating Income (Expense)	$259.7K	-$11.9K	$1.6M	-$1.3M	-$469.2K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$39.2M	-$28.2M	-$8.5M	-$3.8M	-$846.0K
Income Tax Expense (Benefit)	$16.9K	$20.8K	$6.0K	$800.00	$800.00
Net Income (Loss) Attributable to Parent	-$39.3M	-$19.0M	-$8.5M	-$3.8M	-$846.8K
Earnings Per Share, Basic	-$1.65	-$1.02	-$0.58	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$23.7M	$18.9M	$31.4M	$8.8M	$2.6K
Assets, Current	$23.7M	—	—	—	$404.2K
Cash and Cash Equivalents, at Carrying Value	$23.4M	$18.5M	$29.7M	$8.8M	$193.00
Liabilities	$18.0M	$6.5M	$2.7M	$3.3M	$6.8M
Liabilities, Current	$17.2M	$6.4M	$2.3M	$1.3M	$23.1K
Accounts Payable, Current	$3.8M	$3.5M	$509.6K	$1.0M	$224.5K
Stockholders' Equity Attributable to Parent	$8.4M	$28.7M	$5.5M	-$6.8M	-$6.0M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$28.3M	-$14.3M	-$10.7M	-$4.1M	-$218.4K
Net Cash Provided by (Used in) Investing Activities	—	—	—	—	-$64.5M
Net Cash Provided by (Used in) Financing Activities	$33.2M	$7.8M	$31.6M	$12.8M	$100.0K
Payments for Repurchase of Equity	—	—	—	—	$6.3M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)